BidaskClub cut shares of MannKind (NASDAQ:MNKD) from a hold rating to a sell rating in a research report released on Tuesday morning.
Several other research analysts also recently commented on the company. ValuEngine downgraded MannKind from a sell rating to a strong sell rating in a report on Tuesday, November 14th. Zacks Investment Research upgraded MannKind from a sell rating to a hold rating in a report on Wednesday, January 10th. Maxim Group reiterated a hold rating on shares of MannKind in a report on Tuesday, January 30th. Finally, S&P Equity Research reduced their price target on MannKind from $3.49 to $2.77 in a report on Thursday, January 25th. Five research analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of Sell and a consensus price target of $1.59.
MannKind (NASDAQ:MNKD) opened at $2.68 on Tuesday. The company has a market capitalization of $322.85, a PE ratio of -2.39 and a beta of 2.95. The company has a quick ratio of 0.62, a current ratio of 0.65 and a debt-to-equity ratio of -0.48. MannKind has a twelve month low of $0.67 and a twelve month high of $6.96.
In other MannKind news, VP Stuart A. Tross purchased 39,840 shares of MannKind stock in a transaction that occurred on Thursday, December 21st. The shares were bought at an average price of $2.52 per share, for a total transaction of $100,396.80. Following the acquisition, the vice president now directly owns 59,840 shares in the company, valued at $150,796.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.10% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. Dupont Capital Management Corp increased its holdings in MannKind by 99.9% during the 4th quarter. Dupont Capital Management Corp now owns 201,900 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 100,900 shares during the period. Dimensional Fund Advisors LP purchased a new position in MannKind during the 3rd quarter valued at about $270,000. Wells Fargo & Company MN increased its holdings in MannKind by 51.5% during the 3rd quarter. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 30,589 shares during the period. Bank of New York Mellon Corp increased its holdings in MannKind by 30.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 108,380 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 25,125 shares during the period. Finally, Macquarie Group Ltd. purchased a new position in MannKind during the 3rd quarter valued at about $156,000. Institutional investors own 19.62% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “MannKind (MNKD) Downgraded by BidaskClub to “Sell”” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3261027/mannkind-mnkd-downgraded-by-bidaskclub-to-sell.html.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.